Sirtex Medical Limited
(ASX:SRX) has announced that unaudited worldwide dose sales of its SIR-Spheres® Y-90 resin microspheres increased by 16.4 percent over the prior corresponding period.
SIR-Spheres are a medical device used in interventional oncology, specifically Selective Internal Radiation Therapy for the treatment of liver cancers.
The Americas were a strong regional performer, with full year sales growth of 19.2 percent.
Europe, the Middle East and Africa came in at 11.2 percent, while the Asia Pacific Region showed growth of 8.2 percent.
Sirtex Medical Limited reported a net profit of $25.94 million at 31 December 2015.
